5:44 PM
 | 
Jul 18, 2012
 |  BC Extra  |  Clinical News

EnVivo's EVP-6124 meets AD endpoint

EnVivo Pharmaceuticals Inc. (Watertown, Mass.) said once-daily oral EVP-6124 met the co-primary endpoints of improving cognition and clinical function at week 23 vs. placebo in a Phase IIb trial to treat mild to moderate Alzheimer's disease (AD). Cognition...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >